• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

18.94 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306
Open 18.94
Bid (Size) 18.50 (100)
Ask (Size) 19.29 (400)
Prev. Close 18.94
Today's Range 18.94 - 18.94
52wk Range 6.500 - 28.66
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
October 22, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From Vor Biopharma
Via GlobeNewswire

Performance

52-Week Range 33.9% below 52-week high
18.94
6.5052W Low 28.6652W High
1 Week 4.3% below 1-week high
17.731W Low 19.791W High

Vor Biopharma Inc. - Common Stock (VOR) traded between $6.50 and $28.66 over the past 52 weeks and last traded at $18.94, 33.9% below its 52-week high. Over the past week it ranged between $17.73 and $19.79.

Past 12 Months
+5.0%
-13.9%
-0.2%
+29.5%
+62.7%
-28.5%
1W +$0.91
1M -$3.06
3M -$0.04
6M +$4.32
YTD +$7.30
1Y -$7.56

VOR was -28.5% over the past year, +29.5% over six months, +62.7% year to date, +5.0% in the last week.

12 Months vs Market
VOR
-28.5%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months VOR returned -28.5% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg
Today 306 3-mo avg 951.1K
1W
759.2K
1M
1.1M
3M
951.1K
6M
1.1M
YTD
1.1M
1Y
1.2M

VOR most recently traded 306 shares against a 3-month average daily volume of 951.1K.

More News

Read More
News headline image
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
September 08, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio To Participate in Upcoming September Conferences
September 01, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
News headline image
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints David Zaccardelli to Board of Directors
July 07, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
June 08, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 08, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 30, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
What's Behind The Jump In Vor Biopharma Stock? ↗
March 27, 2026
Via Benzinga
News headline image
Vor Bio Announces $75 Million Private Placement with TCGX
March 27, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026
From Vor Biopharma
Via GlobeNewswire

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 18.94
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 1.27B
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap